Loading...
Market
What will be the revenue generated by Lenacapavir in its first full year of sales by end of 2025?
2
Resolution / Starting Odds
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Gilead's financial reports and earnings releases
Story
Gilead's $GILD Twice-Yearly Lenacapavir Shows 96% Reduction in HIV Infections in Phase 3 Trial
Sep 12, 2024, 12:43 PM
Gilead Sciences ($GILD) has announced that its twice-yearly HIV prevention drug, Lenacapavir, has shown a 96% reduction in HIV infections in its second pivotal Phase 3 trial. The trial demonstrated the drug's superiority over the daily Truvada regimen. As a result of these positive interim results, Gilead has stopped the blinded phase of the trial and will offer Lenacapavir to all participants in an open-label phase. The trial, known as PURPOSE 2, met its key endpoints, showing significant efficacy in reducing HIV infections compared to the background HIV incidence. Notably, 99.9% of participants in the Lenacapavir group did not acquire HIV, with only 2 cases reported among 2,180 participants. Gilead's antiviral HIV prevention shot has demonstrated 96% efficacy.
View original story
Similar markets
Below $10,000 per year • 25%
$10,000 - $20,000 per year • 25%
$20,000 - $30,000 per year • 25%
Above $30,000 per year • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
North America • 25%
Europe • 25%
Africa • 25%
Asia • 25%
Less than 50% • 25%
50% to 75% • 25%
76% to 99% • 25%
100% or more • 25%
Global Fund • 25%
PEPFAR • 25%
Gilead Sciences • 25%
Other • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than 10% • 25%
10%-30% • 25%
31%-50% • 25%
More than 50% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
1-4 countries • 25%
5-9 countries • 25%
10-14 countries • 25%
15 or more countries • 25%